- $40.52m
- $22.11m
- $0.05m
Brief: INmune Bio Presents New Biomarker And Feasibility Data From Phase 1b Study Supporting The Use Of XPro To Treat Alzheimer’s Disease At Clinical Trials
Brief: Inmune Bio Announces Approval Of Clinical Trial Application By U.K. Regulator For Phase 2 Clinical Trial In Alzheimer’s Disease
INmune Bio Inc reports results for the quarter ended in June - Earnings Summary
INmune Bio Inc expected to post a loss of 40 cents a share - Earnings Preview
INmune Bio Inc expected to post a loss of 40 cents a share - Earnings Preview
Brief: INmune Bio Announces Novel MRI Biomarker Data Demonstrating Improvement In Gray Matter In Patients With Alzheimer’S Disease
U.S. RESEARCH ROUNDUP-Advance Auto Parts, Target, Xylem
INmune Bio up as FDA allows prostate cancer therapy study
Brief: Inmune Bio Inc. Announces First Quarter 2023 Results And Provides Business Update
INmune Bio Inc expected to post a loss of 2 cents a share - Earnings Preview
Brief: Inmune Bio Inc says entered second amendment to exclusive license agreement to PITT agreement
Brief: Inmune Bio Inc Entered Into Additional Amendment To Inkmune Agreement
INmune Bio up on positive data for Alzheimer's drug in animal model
Brief: Xpro1595 Improves Outcomes In A Mouse Model Of Tbi-Induced Alzheimer’S Disease
INmune Bio rises on applying to start human trial of cancer therapy
INmune Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: Inmune Bio, Inc. Announces 2022 Results And Provides Business Update
INmune Bio Inc expected to post a loss of 48 cents a share - Earnings Preview
Brief: INmune Bio To Report Q4, 2022 Results, Provide Corporate Update On March 2